Outcome MeasureAnxiety

GAD-7

Generalized Anxiety Disorder 7-item Scale

17 Papers in Blossom

About This Instrument

The Generalized Anxiety Disorder 7-item (GAD-7) scale is a brief self-report questionnaire developed by Robert Spitzer and colleagues in 2006 to screen for and measure the severity of generalized anxiety disorder. Each of the 7 items asks how often the respondent has been bothered by a specific anxiety symptom over the past two weeks, rated 0–3 (not at all to nearly every day). Total scores range from 0 to 21. While developed for GAD, the scale also performs well as a screener for panic disorder, social anxiety disorder, and PTSD. The GAD-7 is widely used as a secondary endpoint in psychedelic clinical trials due to its brevity, free public-domain availability, and strong psychometric properties (sensitivity 89%, specificity 82% at cutoff ≥10). It is often paired with the PHQ-9 for combined depression and anxiety assessment.

Clinical Thresholds

021
Minimal
Score 04
Mild
Score 59
Moderate
Score 1014
Severe
Score 1521

Outcome Data Across Studies

Reported results for GAD-7 across 12 studies with quantitative data.

Outcome data across 39 study arm–timepoint observations
SD
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder
2021Secondary
Esketamine + oral antidepressant(experimental)08315.24.0
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder
2021Secondary
Esketamine + oral antidepressant(experimental)0317.83.7
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder
2021Secondary
Placebo + oral antidepressant(active_comparator)07915.13.5
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder
2021Secondary
Placebo + oral antidepressant(active_comparator)0307.73.6
Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
2022Secondary
Bipolar disorder(experimental)05014.35.5
Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
2022Secondary
OCD(experimental)05012.95.4
Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
2022Secondary
Bipolar disorder(experimental)1418.3
Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression
2022Secondary
OCD(experimental)1415.5
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)01912.95.9
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)21198.8

Papers Using GAD-7

Quick Facts

Full Name
Generalized Anxiety Disorder 7-item Scale
Domain
Anxiety
Papers Indexed
17
Score Range
021
Interpretation
Lower = better
Unit
points
Reference
Visit
All Measures